| Document |
Document Title |
|
WO/2000/059884A1 |
The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatmen...
|
|
WO/2000/059880A1 |
The present invention relates to cinnamide compounds of formula (I), in which at least one of R¿1? to R¿5? is a '$i(cis)-cinnamide' (a) or a '$i(trans)-cinnamide' (b) and the other variables are as defined in the claims, that are usefu...
|
|
WO/2000/055147A1 |
The present invention relates to fused 1,4-thiazine-2-carbonitrile derivatives, compositions thereof and methods for preparing the compounds. The compounds are useful in the treatment of diseases of the central nervous system, the cardio...
|
|
WO/2000/054759A2 |
The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The c...
|
|
WO/2000/051992A1 |
Compounds of Formulae (I) and (II), and their $i(N)-oxides and agriculturally suitable salts, are disclosed which are useful as fungicides wherein Z is O, S(O)¿n? or NR?5¿; n is 0, 1, or 2; Q is O or S; G is, together with the two link...
|
|
WO/2000/050380A1 |
The present invention relates to compounds that are a useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous s...
|
|
WO/2000/050414A1 |
The present invention relates to novel hypolipidemic, antihyperglycemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutical...
|
|
WO2000012076A9 |
Disclosed are nitrosated and/or nitrosylated compounds of formulae (I)-(XIX) which are phosphodiesterase inhibitors and compositions comprising them. The invention also provides methods for treating or preventing sexual dysfunctions in m...
|
|
WO/2000/044709A2 |
Compound of the formula (B) are useful in treating disease conditions mediated by TNF-$g(a), such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage l...
|
|
WO/2000/041685A1 |
CCR-3 receptor antagonists and novel methods for their use are provided.
|
|
WO/2000/042031A2 |
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1, 3-thiazolidines, 2-arylimino-2, 3, 4, 5-tetrahydro-1, 3-thiazines, 2-arylimino-1, 3-thiazolidin-4-ones, 2-arylimino-1, 3-thiazolidin-5-ones, and 2-arylimino-1, ...
|
|
WO/2000/032175A2 |
The invention provides pharmaceutical non-peptidic organic compounds capable of interacting with a functionally defective form of a mutant or a wild-type tumor suppressor protein of the p53 family (such as p53, p63 or p73). The interacti...
|
|
WO/2000/023425A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or preventionof conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PP...
|
|
WO/2000/016603A2 |
This invention relates generally to novel bridged heterocyclic compounds, and their preparation and use for preventing and/or treating neurological disorders, including physically damaged nerves and neurodegenerative diseases; for treati...
|
|
WO/2000/017173A1 |
The invention relates to compounds of formula (I) and their tautomeric and isomeric forms and salts, as well as to a method for producing said compounds and their use in medicines.
|
|
WO/2000/012084A1 |
The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treat...
|
|
WO/2000/009106A2 |
This invention relates to novel compositions and uses of carboxylic acid or isostere of a heterocyclic ring compound having two or more heteroatoms within the heterocyclic ring and wherein the heterocyclic ring has at least one substitue...
|
|
WO/2000/009479A2 |
This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using heterocyclic thioesters and ketones.
|
|
WO/2000/009492A1 |
A compound of formula (I), wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿ and Q are as defined, useful in the treatment of arthritis, cancer, and other diseases involving the dysregulated production/release of reprolysins such as TNF a...
|
|
WO/2000/006585A1 |
Nitric acid salts with medicines active in bony disorders.
|
|
WO/2000/004892A2 |
This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development ...
|
|
WO/2000/000465A1 |
The invention provides hydrazine derivatives of formula (I) wherein R?1¿ is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R?2¿ is an acyl group derived from an $g(a)-, $g(b)-, $g(...
|
|
WO/1999/067230A1 |
The present invention relates to compound of formula (I), that are potent inhibitors of $g(a)¿4?$g(b)¿1? mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the m...
|
|
WO/1999/062888A1 |
The present invention is directed to novel carboxylic acids and isosteres of heterocyclic ring compounds of formula (I) which have multiple heteroatoms within the heterocyclic ring, novel derivatives containing N-linked diketos, sulfonam...
|
|
WO/1999/062891A1 |
Certain thiazolidinone and metathiazanone compounds, as described, are useful as potassium channel inhibitors and are especially useful for the treatment of cardiac arrhythmias and other diseases, conditions and disorders.
|
|
WO/1999/062487A1 |
This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using heterocyclic esters or amides.
|
|
WO/1999/058531A1 |
The present application describes novel substituted aryl hydroxamic acids of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected from N,...
|
|
WO/1999/055690A1 |
This invention relates to guanidine derivatives of formula (I) wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising...
|
|
WO/1999/055673A1 |
The invention relates to novel arylphenyl-substituted cyclic keto enols of formula (I), wherein X represents halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl halide, halogenalkoxy, halogenalkenyloxy, nit...
|
|
WO/1999/050257A1 |
This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of ...
|
|
WO/1999/043649A1 |
The invention relates to new arylphenyl-substituted cyclic keto-enols of the formula (I), where X is halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkyl sulfinyl, alkyl sulfonyl, halogen alkyl, halogen alkoxy, halogen alkenyloxy, nitro,...
|
|
WO/1999/043670A1 |
Disclosed are compounds of formula (I) or pharmaceutically acceptable addition salts thereof wherein: Y represents oxygen or sulfur; Z is nitrogen or CH; R¿1?, R¿2? and R¿3? represents hydrogen, halogen, hydroxy, alkoxy, alkyl, triflu...
|
|
WO/1999/041246A1 |
The present application describes novel lactams and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring B is a 4-8 membered cyclic sulfonamide containing from 0-3 additional heteroatoms sele...
|
|
WO/1999/025388A1 |
Novel biological stain compositions that are adapted for human $i(in vivo) topical application. In particular, novel Toluidine Blue O, TBO, dye products, products which contain TBO and specific TBO derivatives are disclosed.
|
|
WO/1999/025687A1 |
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-...
|
|
WO/1999/024411A1 |
The present invention relates to a novel receptor, in particular to a new type of receptor with an affinity for compounds of the oxazoline class, compounds which bind to this receptor, and the use of these compounds in the treatment of d...
|
|
WO/1999/023092A2 |
Disclosed are compounds of formula (I) or the pharmaceutically acceptable acid addition salts thereof, wherein: Ar represents aryl or heteroaryl; R¿1? and R¿2? are the same or different and represent organic or inorganic substituents; ...
|
|
WO/1999/021560A1 |
Phenothiazines of formula (I) where R¿1? is H or -COOR, where R is selected from the group consisting of branched or unbranched alkyl groups containing from 1 to 4 carbon atoms, and where X is selected from H, branched or unbranched alk...
|
|
WO/1999/020614A1 |
The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmac...
|
|
WO/1999/019313A1 |
Novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.
|
|
WO/1999/016758A1 |
The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmace...
|
|
WO/1999/014998A2 |
The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering sensorineurotrophic compounds described below. The invention rel...
|
|
WO/1999/012888A1 |
The invention relates to a method for producing aryloligoamines, characterised in that an amine is reacted with an activated aromatic and a base within a temperature range from 0 and 150 °C in the presence of a palladium constituent and...
|
|
WO/1999/012915A1 |
The invention relates to compounds of the formula formula (I) and to their production and their use in pharmaceuticals.
|
|
WO/1999/012916A1 |
The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for Formula (1). The compounds ...
|
|
WO/1999/009991A1 |
Disclosed are the novel compounds represented by structural Formula (I), wherein A is a lipophilic group comprising an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group a...
|
|
WO/1999/006390A1 |
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mamma...
|
|
WO/1999/006391A1 |
The disclosed invention includes pharmaceutical compositions and methods for treating inflammatory conditions, particularly those that are characterized by increased binding of alpha-9 integrin to one or more of its ligands. Also disclos...
|
|
WO/1999/002146A1 |
Compounds represented by general formula (I), salts thereof and type N calcium channel inhibitors containing the same as the active ingredient, wherein R?1¿ represents optionally substituted alkyl, alkoxy or phenyl, a heterocyclic group...
|
|
WO/1999/001428A1 |
Hydrazine derivatives of formula (I) wherein Y signifies CO or SO¿2?; R?1¿ signifies lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R?2¿ signifies lower alkyl, halo-lower alkyl, a...
|
